Table 2.

Cholangiocarcinoma studies n (%)

Author	Type of microsphere	Type of mets (patients)	Response criteria	Response	Median OS
(publish date and study type)	(average dosage or activity)		@ 1st assessment
Ibrahim et al[69]	Therasphere	ICC (24)	WHO	6 (27) PR	14.9 mo
(10/2008, PC)	(median 105.1 Gy)		@ 1 mo	15 (68) SD
				1 (5) PD	31.8 mo (solitary)
				2 lost	6.1 mo (extrahepatic disease)
Saxena et al[71]	SIR-Spheres	ICC (25)	RECIST	6 (26) PR	9.3 mo
(2/2010, PC)	(mean 1.76 Gbq)		@ 8.1 mo (median)	11 (48) SD
				5 (22) PD
				2 lost
Haug et al[68]	SIR-Spheres	ICC (26)	RECIST	5 (22) PR	11.7 mo
(6/2011, PC)	(no dosage info)		@ 2.8 mo	15 (65) SD
				3 (13) PD
				3 lost
Hoffmann et al[3]	SIR-Spheres	ICC (33)	RECIST	12 (36) PR	22 mo
(2/2012, RS)	(median 1.54 Gbq)		@ 3 mo	17 (52) SD
				4 (12) PD
Rafi et al[70]	SIR-Spheres	ICC (19)	RECIST	2 (11) PR	11.5 mo
(4/2013, PC)	(mean 1.20 Gbq)		@ 3 mo	13 (68) SD
				4 (21) PD
Mouli et al[74]	Therasphere	ICC (46)	WHO	11 (25) PR	No median OS
(8/2013, PC)	(no dose info)	Note: overlaps with Ibrahim et al	@ 1 mo	33 (73) SD 1 (2) PD	14.6 mo (solitary) 5.7 mo (multifocal)
Camacho et al[72]	SIR-Spheres	ICC (21)	RECIST	RECIST	16.3 mo
(2/2014, PC)	(no dose info)		mRECIST	1 (4.7) PR
			EASL	16 (76.2) SD
			@ 1 mo	4 (19.1) PD
				mRECIST
				13 (62.0) PR
				4 (19.0) SD
				4 (19.0) PD
				EASL
				2 (9.5) PR
				15 (71.4) SD
				4 (19.1) PD
Filippi et al[73]	SIR-Spheres	ICC (18)	PERCIST	14 (82.3) PR	14.8 mo
(8/2014, PC)	(not given)		@ unspecified	3 (17.6) SD

ICC: Intrahepatic cholangiocarcinoma; PC: Prospective cohort study; RS: Retrospective study; CR: Complete response; PR: Progressive response; PD: Progressive disease; SD: Stable disease; OS: Overall survival; OR: Overall response.